tbuckley/cabot-search huggingface dataset:
PARIS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment patterns and outcomes of patients with metastatic colorectal cancer in third-line and beyond systemic therapy: Real-world data from a setting with limited resources.
Authors: Alexandre A. Jácome, Roberto Almeida Gil, Eduardo Dias de Moraes, Renata D'Alpino Peixoto, Jorge Alexandre Canedo, Thais Passarini, Mariana Gil, Sabrina Pereira, Larissa Amorim, Gabriel Prolla, Laura Freitas, Fernanda Coelho, Isabela Paiva, Rafael Paes, Heloisa Cruz, Matheus Costa e Silva, Carlos Gil Ferreira, Bruno Lemos Ferrari, Bernardo Garicochea, Rodrigo Dienstmann
Journal: Journal of Clinical Oncology (2022)

58 Background: Regorafenib and trifluridine/tipiracil (TAS-102) are the only therapeutic options for patients with chemorefractory metastatic colorectal cancer (mCRC) with demonstrated benefit in overall survival (OS). However, they are not accessible worldwide. In Brazil, they have been recently approved, but they have not yet been provided by public health system or private health insurances. We aimed to describe the treatment patterns and clinical outcomes of that population in a setting with limited access to those drugs. Methods: Retrospective study evaluating 510 patients with mCRC who were treated at five Oncoclinicas centers in Brazil from January 2011 to December 2019. Demographic and clinical data were retrieved from electronic medical records. The median OS was calculated by Kaplan-Meier method and prognostic factors were evaluated via multivariable Cox Regression, calculating the Hazard Ratio (HR) and the confidence interval (CI95%). Results: A total of 163 patients (33% of the overall population) received third-line and 73 (15%) fourth-line systemic therapy. Median age was 62 years, 59% were male. Tumors were right-sided in 19%, RAS mutated 44%, BRAF mutated 3%, and high-frequency microsatellite instability 3%. Metastasectomy prior to third-line was performed in 62% of the patients. From the start of third-line therapy, median follow-up was 9.0 months, with 67% of deaths, and median OS was 13.7 months (CI95% 11.8m–20.0m). Most adopted regimens in third-and fourth-line were (1) rechallenge with oxaliplatin-based therapy (39% and 26%, respectively); (2) rechallenge with irinotecan-based therapy (32% and 34%); (3) rechallenge with anti-EGFR monoclonal antibodies (20% and 29%); (4) regorafenib (13% and 25%); and (5) TAS-102 (2% and 4%). In multivariable model including clinical and molecular variables, prior metastasectomy was the only significant prognostic factor for OS (HR 0.51, CI95% 0.31–0.83, p=0.007). Conclusions: In real-world, a meaningful proportion of patients with mCRC are eligible for third and later lines of therapy. Rechallenge with chemotherapy and anti-EGFR agents is overused in a setting of limited access to therapies with demonstrated OS benefit, such as regorafenib and TAS-102. Barriers to drug access impair the adoption of the best evidence-based continuum of care and strategies to overcome them are urgently needed. Refractory patients in later lines of therapy derive survival benefit from prior metastasectomy.
Instructions to Authors
Journal: Cardiovascular Research (2005)

It should be structured into the subsections 'Objective', 'Methods', 'Results' and 'Conclusion(s)'.Give the name of the animal species, if applicable, in the subsection 'Methods'.(3) Keywords.These will be published with your article.During online submission, they are typed into a window.A maximum of 5 keywords is required for publication of the
Science during COVID-19: where do we go from here?
Authors: None The Lancet
Journal: The Lancet (2020)

The emergence of COVID-19 has indelibly marked science and medicine this year. Advances in epidemiology, clinical care, prevention, treatment, and the speed of vaccine development have been unprecedented, driven by global collaboration and data sharing. None of that would have been possible without the tireless work, sacrifice, dedication, and insight of scientists and researchers worldwide, from those working in laboratories to the principal investigators of clinical trials and everyone in between.
Malformations of the Genital Organs of Woman.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary
Authors: Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting
Journal: Journal of the American College of Cardiology (2011)
Significance of cyclic variation of integrated backscatter in intravascular ultrasound radio-frequency signal analysis for coronary atherosclerosis Nobuyuki Komiyama, Akio Oshima, Matthew L. Kolz, Brian Courtney, Paul G. Yock, Peter J. Fitzgerald. Chiba University Hospital, Chiba, Japan, Stanford University Medical Center, Stanford, CA
Journal: Journal of the American College of Cardiology (2001)
Missing Degrees in Byline and Errors in Equation
Authors: Phillip Knebel
Journal: JAMA Surgery (2020)

Alfonso W. Avolio, MD; Antonio Franco, MD; Andrea Schlegel, MD, PhD; Quirino Lai, MD, PhD; Sonia Meli, MD; Patrizia Burra, MD, PhD; Damiano Patrono, MD; Matteo Ravaioli, MD; Domenico Bassi, MD; Fabio Ferla, MD; Duilio Pagano, MD; Paola Violi, MD, PhD; Stefania Camagni, MD; Daniele Dondossola, MD; Roberto Montalti, MD; Wasfi Alrawashdeh, MD; Alessandro Vitale, MD, PhD; Luciana Teofili, MD; Gabriele Spoletini, MD, PhD; Paolo Magistri, MD; Marco Bongini, MD; Massimo Rossi, MD; Vincenzo Mazzaferro, MD, PhD; Fabrizio Di Benedetto, MD; John Hammond, MD, PhD; Marco Vivarelli, MD; Salvatore Agnes, MD; Michele Colledan, MD; Amedeo Carraro, MD, PhD; Matteo Cescon, MD, PhD; Luciano De Carlis, MD; Lucio Caccamo, MD, PhD; Salvatore Gruttadauria, MD, PhD; Paolo Muiesan, MD; Umberto Cillo, MD; Renato Romagnoli, MD; Paolo De Simone, MD, PhD
AN INTRODUCTION TO THE STUDY OF PNEUMONIC FEVER.
Authors: EDWARD F. WELDS
Journal: JAMA (1889)

SIXTH PAPER. PREVALENCE—METEOROLOGY. The relations existing between meteorological conditions and pneumonic fever are of the most interesting nature, and many and various are the rules and laws relating thereto that have been formulated by systematic writers, but the exceptions to them are so numerous and important that they are greatly weakened or rendered entirely nugatory. It may be affirmed, as a general proposition, ¹ that pneumonic fever will be found to prevail to a greater extent than ordinarily, the influence of season and epidemics excepted, when the daily range of temperature, ² humidity of the atmosphere, ³ velocity of the wind, range of barometer, amount of atmospheric pressure" and amount of ozone present in the air are greater than the average, and that it will be less prevalent when opposite conditions prevail. Again, it will be found that an excess of cases will be met with when the range of
Involvement of Multiple Variants of Soluble <scp>CD146</scp> in Systemic Sclerosis: Identification of a Novel Profibrotic Factor
Authors: Marie Nollet, Richard Bachelier, Ahmad Joshkon, Waël Traboulsi, Amandine Mahieux, Anais Moyon, Alexandre Muller, Indumathi Somasundaram, Stéphanie Simoncini, Franck Peiretti, Aurélie S. Leroyer, Benjamin Guillet, Brigitte Granel, Françoise Dignat‐George, Nathalie Bardin, Alexandrine Foucault‐Bertaud, Marcel Blot‐Chabaud
Journal: Arthritis & Rheumatology (2022)

Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive fibrosis, immune dysfunction, and vascular damage, in which the expression of many growth factors is deregulated. CD146 was recently described as a major actor in SSc. Since CD146 also exists as a circulating soluble form (sCD146) that acts as a growth factor in numerous angiogenic- and inflammation-related pathologies, we sought to identify the mechanisms underlying the generation of sCD146 and to characterize the regulation and functions of the different variants identified in SSc.We performed in vitro experiments, including RNA-Seq and antibody arrays, and in vivo experiments using animal models of bleomycin-induced SSc and hind limb ischemia.Multiple forms of sCD146, generated by both shedding and alternative splicing of the primary transcript, were discovered. The shed form of sCD146 was generated from the cleavage of both long and short membrane isoforms of CD146 through ADAM-10 and TACE metalloproteinases, respectively. In addition, 2 novel sCD146 splice variants, I5-13-sCD146 and I10-sCD146, were identified. Of interest, I5-13-sCD146 was significantly increased in the sera of SSc patients (P < 0.001; n = 117), in particular in patients with pulmonary fibrosis (P < 0.01; n = 112), whereas I10-sCD146 was decreased (P < 0.05; n = 117). Further experiments revealed that shed sCD146 and I10-sCD146 displayed proangiogenic activity through the focal adhesion kinase and protein kinase Cε signaling pathways, respectively, whereas I5-13-sCD146 displayed profibrotic effects through the Wnt-1/β-catenin/WISP-1 pathway.Variants of sCD146, and in particular the novel I5-13-sCD146 splice variant, could constitute novel biomarkers and/or molecular targets for the diagnosis and treatment of SSc and other angiogenesis- or fibrosis-related disorders.
rPSGL-Ig inhibits in-stent restenosis in porcine coronary arteries after double injury Jean-Francois Tanguay, Pascale Geoffroy, Jean-Francois Theoret, Robert G. Schaub, Anjali Kumar, Yahye Merhi. Montreal Heart Institute, Montreal, PQ, Canada, Wyeth/ Genetics Institute, Andover, MA
Journal: Journal of the American College of Cardiology (2001)
Use of Wearables and Implantable Devices to Monitor Pulmonary Health in the Outpatient Setting
Authors: Vladimir Glinskii, Raquel Lyn, Christopher Thomas, Vinicio A. de Jesus Perez
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Use of Wearables and Implantable Devices to Monitor Pulmonary Health in the Outpatient Setting." American Journal of Respiratory and Critical Care Medicine, 205(2), pp. 242–244
CONTRIBUTORS TO THIS ISSUE
Authors: Erik Berglund, Walter Bloom, Hans Borst, Robert Boucek, Eugene Bkaunwald, Daniel Brody, F Bumptjs, Abraham Cherbakoff, Thomas Clarkson, S Massengill, Tenn Hadley, L Conn, Richard Emanuel, Eugene Ferris, Noble Fowler, Robert Funkhouser, Richard Goodwin, W Hamilton, Carroll Handley, Donald Heiman, J Jones, Claude Joyner, Louis Ivatz, William Lacy
Journal: Circulation Research (1957)
VEGF cDNA gene therapy postmyocardial infarction: New strategy to reduce adverse ventricular remodeling postinjury Masoud Sadreddini, Fayez Dawood, Duncan Stewart, Anne Opavsky, Sam Siu, Peter Liu. Heart &amp; Stroke/Richard Lewar Centre of Excellence, Toronto, ON, Canada
Journal: Journal of the American College of Cardiology (2001)
Effect of clopidogrel loading before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors Abid Assali, Stefano Sdringola, Joseph Salloum, Ali Moustapha, Mohammed Ghani, George Schroth, H. V. Anderson, Richard W. Smalling, Oscar Rosales. University of Texas Medical School, Houston, TX
Journal: Journal of the American College of Cardiology (2001)
AMERICAN MEDICAL ASSOCIATION.CONSTITUTION AND BY-LAWS.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Moment-based representation of the diffusion inside the brain from reduced DMRI acquisitions: Generalized AMURA
Authors: Santiago Aja-Fernández, Tomasz Pieciak, Carmen Martín-Martín, Álvaro Planchuelo-Gómez, Rodrigo de Luis-García, Antonio Tristán-Vega
Journal: Medical Image Analysis (2022)

AMURA (Apparent Measures Using Reduced Acquisitions) was originally proposed as a method to infer micro-structural information from single-shell acquisitions in diffusion MRI. It reduces the number of samples needed and the computational complexity of the estimation of diffusion properties of tissues by assuming the diffusion anisotropy is roughly independent on the b-value. This simplification allows the computation of simplified expressions and makes it compatible with standard acquisition protocols commonly used even in clinical practice. The present work proposes an extension of AMURA that allows the calculation of general moments of the diffusion signals that can be applied to describe the diffusion process with higher accuracy. We provide simplified expressions to analytically compute a set of scalar indices as moments of arbitrary orders over either the whole 3-D space, particular directions, or particular planes. The existing metrics previously proposed for AMURA (RTOP, RTPP and RTAP) are now special cases of this generalization. An extensive set of experiments is performed on public data and a clinical clase acquired with a standard type acquisition. The new metrics provide additional information about the diffusion processes inside the brain.
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Authors: Shipeng He, Guoqiang Dong, Junfei Cheng, Ying Wu, Chunquan Sheng
Journal: Medicinal Research Reviews (2022)

Abstract Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development. Currently, the largest challenge in the molecular design and drug development of PROTACs is efficient identification of potent and drug‐like degraders. This review aims to comprehensively summarize and analyse state‐of‐the‐art methods and strategies in the design of PROTACs. We provide a detailed illustration of the general principles and tactics for designing potent PROTACs, highlight representative case studies, and discuss the advantages and limitations of these strategies. Particularly, structure‐based rational PROTAC design and emerging new types of PROTACs (e.g., homo‐PROTACs, multitargeting PROTACs, photo‐control PROTACs and PROTAC‐based conjugates) will be focused on.
Author Correction: Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
Authors: Lin Wang, Dominik Aschenbrenner, Zhiyang Zeng, Xiya Cao, Daniel Mayr, Meera Mehta, Melania Capitani, Neil Warner, Jie Pan, Liren Wang, Qi Li, Tao Zuo, Sarit Cohen-Kedar, Jiawei Lu, Rico Chandra Ardy, Daniel J. Mulder, Dilan Dissanayake, Kaiyue Peng, Zhiheng Huang, Xiaoqin Li, Yuesheng Wang, Xiaobing Wang, Shuchao Li, Samuel Bullers, Anís N. Gammage, Klaus Warnatz, Ana-Iris Schiefer, Gergely Krivan, Vera Goda, Walter H. A. Kahr, Mathieu Lemaire, Helen R. Griffin, Sophie Hambleton, Chien-Yi Lu, Iram Siddiqui, Michael G. Surette, Daniel Kotlarz, Karin R. Engelhardt, Helen R. Griffin, Robert Rottapel, Hélène Decaluwe, Ronald M. Laxer, Michele Proietti, Sophie Hambleton, Suzanne Elcombe, Cong-Hui Guo, Bodo Grimbacher, Iris Dotan, Siew C. Ng, Spencer A. Freeman, Scott B. Snapper, Christoph Klein, Kaan Boztug, Ying Huang, Dali Li, Holm H. Uhlig, Aleixo M. Muise
Journal: Nature Genetics (2022)
Fine-tuning of polyaspartamide derivatives with alicyclic moieties for systemic mRNA delivery
Authors: Jongmin Yum, Beob Soo Kim, Satomi Ogura, Rimpei Kamegawa, Mitsuru Naito, Yuichi Yamasaki, Hyun Jin Kim, Kanjiro Miyata
Journal: Journal of Controlled Release (2022)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Authors: F. Cardoso, S. Paluch-Shimon, E. Senkus, G. Curigliano, M.S. Aapro, F. André, C.H. Barrios, J. Bergh, G.S. Bhattacharyya, L. Biganzoli, F. Boyle, M.-J. Cardoso, L.A. Carey, J. Cortés, N.S. El Saghir, M. Elzayat, A. Eniu, L. Fallowfield, P.A. Francis, K. Gelmon, J. Gligorov, R. Haidinger, N. Harbeck, X. Hu, B. Kaufman, R. Kaur, B.E. Kiely, S.-B. Kim, N.U. Lin, S.A. Mertz, S. Neciosup, B.V. Offersen, S. Ohno, O. Pagani, A. Prat, F. Penault-Llorca, H.S. Rugo, G.W. Sledge, C. Thomssen, D.A. Vorobiof, T. Wiseman, B. Xu, L. Norton, A. Costa, E.P. Winer
Journal: Annals of Oncology (2020)
Neurobiological Mechanisms of Nicotine Reward and Aversion
Authors: Lauren Wills, Jessica L. Ables, Kevin M. Braunscheidel, Stephanie P.B. Caligiuri, Karim S. Elayouby, Clementine Fillinger, Masago Ishikawa, Janna K. Moen, Paul J. Kenny
Journal: Pharmacological Reviews (2022)

Neuronal nicotinic acetylcholine receptors (nAChRs) regulate the rewarding actions of nicotine contained in tobacco that establish and maintain the smoking habit. nAChRs also regulate the aversive properties of nicotine, sensitivity to which decreases tobacco use and protects against tobacco use disorder. These opposing behavioral actions of nicotine reflect nAChR expression in brain reward and aversion circuits. nAChRs containing <i>α</i>4 and <i>β</i>2 subunits are responsible for the high-affinity nicotine binding sites in the brain and are densely expressed by reward-relevant neurons, most notably dopaminergic, GABAergic, and glutamatergic neurons in the ventral tegmental area. High-affinity nAChRs can incorporate additional subunits, including <i>β</i>3, <i>α</i>6, or <i>α</i>5 subunits, with the resulting nAChR subtypes playing discrete and dissociable roles in the stimulatory actions of nicotine on brain dopamine transmission. nAChRs in brain dopamine circuits also participate in aversive reactions to nicotine and the negative affective state experienced during nicotine withdrawal. nAChRs containing <i>α</i>3 and <i>β</i>4 subunits are responsible for the low-affinity nicotine binding sites in the brain and are enriched in brain sites involved in aversion, including the medial habenula, interpeduncular nucleus, and nucleus of the solitary tract, brain sites in which <i>α</i>5 nAChR subunits are also expressed. These aversion-related brain sites regulate nicotine avoidance behaviors, and genetic variation that modifies the function of nAChRs in these sites increases vulnerability to tobacco dependence and smoking-related diseases. Here, we review the molecular, cellular, and circuit-level mechanisms through which nicotine elicits reward and aversion and the adaptations in these processes that drive the development of nicotine dependence. <h3>Significance Statement</h3> Tobacco use disorder in the form of habitual cigarette smoking or regular use of other tobacco-related products is a major cause of death and disease worldwide. This article reviews the actions of nicotine in the brain that contribute to tobacco use disorder.
ARGUMENTUM AD HOMINEM.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Paediatric Cardiology
Authors: Richard D. Rowe
Journal: JAMA (1969)

A new book on pediatric cardiology from the United Kingdom offered the prospect of a portrayal different from that seen in several recent United States newcomers or revamped oldsters. Dr. Hamish Watson, who edited the work, has assembled 68 chapters by 39 contributors in almost 1,000 pages. Well over half the contributors are from the United States, but the omission of contributions from pediatric cardiologists who have amassed enormous clinical experience below the 55th parallel in the United Kingdom seems an extraordinary one. One in five of the authors is an internist, and all have made important contributions to the subject previously. The inclusion of physicians working with adolescents and adults, while facilitating a broad view of the picture of heart malformation, unfortunately tends to reintroduce an old error: the internist concentrates on what for him is the "big picture," ie, the big child, to the deemphasis of larger problems